APPENDIX C
Healthcare Provider Perception of Boxed Warning Information Survey
Survey Questionnaire: Vulvar and Vaginal Atrophy Scenario
Version: 10/23/20
Prescriber Survey to Assess Boxed Warnings Perceptions
Survey Questionnaire: Vulvar and Vaginal Atrophy
(Questions used for pre-testing condition are included at the end)
Introductory Script:
Thank you for your participation in this survey. The first few questions will focus on the condition of vulvar and vaginal atrophy in menopause, which you may also know as postmenopausal atrophic vaginitis.
//PROGRAMMING NOTES: Display each question on its own separate screen. Do not allow participants to go back on any screen. Include soft prompts for all items. //
Question Type: Single Punch
Question Q1
Variable Name: Q1
Variable Label: Q1 Familiarity with treating VVA
Question Text: How experienced are you with treating vulvar and vaginal atrophy?
Value |
Value Label |
1 |
Not at all experienced |
2 |
Slightly experienced |
3 |
Somewhat experienced |
4 |
Experienced |
5 |
Very experienced |
--99 |
Question Type: Single Punch
Question 2
Variable Name: Q2
Variable Label: Q2 Number of patients typically seen
Question Text: How many patients do you typically see for treatment of vulvar and vaginal atrophy?
Value |
Value Label |
1 |
One to two patients a week, or fewer |
2 |
Several patients a week |
3 |
Several patients a day |
98 |
|
--99 |
Refused |
Question Type: Single Punch
Question Q3
Variable Name: Q3
Variable Label: Q3 Bothersomeness of symptoms
Question Text: In general, how bothersome are symptoms of vulvar and vaginal atrophy reported by most of your patients who have the condition?
Value |
Value Label |
1 |
Not at all bothersome |
2 |
Slightly bothersome |
3 |
Somewhat bothersome |
4 |
Bothersome |
5 |
Very bothersome |
98 |
|
--99 |
Refused |
Question Type: Single Punch
Question Q4A
Variable Name: Q4A
Variable Label: Q4A Experience prescribing vaginal inserts
Question Text: Which of the following is true of your prescribing vaginal inserts (e.g., Vagifem, Imvexxy) for the treatment of vulvar and vaginal atrophy?
Value |
Value Label |
1 |
I have written new prescriptions for this product |
2 |
I have only prescribed a refill for this product |
3 |
I have never prescribed this product |
98 |
Unsure/don’t know |
-99 |
// PROGRAMMING NOTE: SKIP 4B if 4A = 2, 3, 4, or 98//
Question Type: Single Punch
Question Q4B
Variable Name: Q4B
Variable Label: Q4B Frequency of prescribing vaginal inserts
Question Text: On average, how often do you prescribe vaginal inserts (e.g., Vagifem, Imvexxy) for the treatment of vulvar and vaginal atrophy?
Value |
Value Label |
1 |
I prescribe this product one or more times a week |
2 |
I prescribe this product a few times a month |
3 |
I prescribe this product a few times a year |
98 |
Unsure/Don’t know |
-99 |
Refused |
Question Type: Multi-Punch
Question Q5
Variable Name: Q5
Variable Label: Q5 Which treatments recommend or prescribe in a month
Question Text: Which of the following other treatments would you recommend or prescribe in a typical month? (Select all that apply.)
Value |
Value Label |
Variable Label |
Q5_1 |
Over-the-counter products (e.g., personal lubricant) |
Q5_1 Typical treatment: OTC products |
Q5_2 |
Vaginal estrogen rings (e.g., Estring, Femring) |
Q5_2 Typical treatment: Estrogen rings |
Q5_3 |
Vaginal estrogen creams (e.g., Premarin, Estrace) |
Q5_3 Typical treatment: Estrogen creams |
Q5_4 |
Topical estrogen gels (e.g., Estrogel, Divigel) |
Q5_4 Typical treatment: Estrogen gels |
Q5_5 |
Oral estrogens (e.g., Premarin) |
Q5_5 Typical treatment: Oral estrogens |
Q5_6 |
Estrogen transdermal patches (e.g., Alora, Estraderm) |
Q5_6 Typical treatment: Estrogen patch |
Q5_7 |
Other prescription product that does not contain estrogen |
Q5_7 Typical treatment: Other prescription product w/o estrogen |
Q5_8 |
Other (specify) |
Q5_8 Typical treatment: Other |
Value |
Value Label |
1 |
Selected |
0 |
Not selected |
For the next few questions, we would like you to consider your patients who are postmenopausal women with vulvar and vaginal atrophy and are complaining of symptoms such as vaginal itching and discomfort or pain during intercourse. They have previously tried over-the-counter ointments with little success.
// PROGRAMMING NOTE: [SHOW SCENARIO AT THE TOP OF THE SCREEN FOR QUESTION 6]//
Question Type: Single Punch
Question Q6
Variable Name: Q6
Variable Label: Q6 Likelihood of discussing inserts
Question Text: How likely are you to discuss vaginal inserts, such as Vagifem or Imvexxy, as a potential option for these patients?
Value |
Value Label |
1 |
Very unlikely |
2 |
Unlikely |
3 |
Somewhat likely |
4 |
Likely |
5 |
Very likely |
-99 |
Refused |
Question Type: Single Punch
Question Q7
Variable Name: Q7
Variable Label: Q7 Risk assessment of vaginal inserts
Question Text: Which of the following statements describe your assessment of the safety of vaginal inserts used to treat vulvar and vaginal atrophy?
Value |
Value Label |
1 |
Risks are minimal for almost all patients |
2 |
Risks are minimal for most patients, but are significant for some patients |
3 |
Risks are significant for most patients |
4 |
I am not familiar enough with vaginal inserts to make an assessment |
-99 |
Refused |
Question Type: Single Punch
Question Q8A
Variable Name: Q8A
Variable Label: Q8A Assessment of inserts vs. oral estrogen
Question Text: Which statement best describes your assessment of the safety of vaginal inserts compared to oral estrogen products?
Value |
Value Label |
1 |
Vaginal inserts are safer than oral estrogen products |
2 |
Vaginal inserts are less safe than oral estrogen products |
3 |
Vaginal inserts are no more and no less safe than oral estrogen products |
4 |
The safety of vaginal inserts versus oral estrogen products has not been established |
5 |
I am not familiar enough with vaginal inserts to make an assessment |
-99 |
Refused |
Question Type: Single Punch
Question Q8B
Variable Name: Q8B
Variable Label: Q8B Assessment of inserts vs. transdermal estrogen
Question Text: Which statement best describes your assessment of the safety of vaginal inserts compared to transdermal estrogen products?
Value |
Value Label |
1 |
Vaginal inserts are safer than transdermal estrogen products |
2 |
Vaginal inserts are less safe than transdermal estrogen products |
3 |
Vaginal inserts are no more and no less safe than transdermal estrogen products |
4 |
The safety of vaginal inserts versus transdermal estrogen products has not been established |
5 |
I am not familiar enough with vaginal inserts to make an assessment |
-99 |
Refused |
Question Type: Single Punch
Question Q8C
Variable Name: Q8C
Variable Label: Q8C Benefits/risks of inserts
Question Text: Which statement best describes your general perspective on the benefits versus risks of vaginal inserts for patients with vulvar and vaginal atrophy.
Value |
Value Label |
1 |
The benefits of vaginal inserts outweigh the risks for most patients |
2 |
The benefits of vaginal inserts outweigh the risks for some, but not most, patients |
3 |
The benefits of vaginal inserts outweigh the risks for very few patients |
4 |
I am not familiar enough with vaginal inserts to make an assessment |
-99 |
Refused |
Question Type: Multi-Punch
Question Q9
Variable Name: Q9
Variable Label: Q9 Factors most important when choosing to prescribe vaginal inserts
Question Text: Which of the following factors play the most important role when deciding whether or not to prescribe vaginal inserts to a patient with vulvar and vaginal atrophy? Please choose the three factors that you consider to be most important.
//PROGRAMMING NOTE: ALLOW PARTICIPANTS TO SELECT UP TO THREE ANSWERS//
[RANDOM ORDER EXCEPT FOR OTHER] [//Multi-punch//]
Variable Name |
Variable Text |
Variable Label |
Q9_1 |
Considerations of this patient’s ability to use the product as prescribed |
Q9_1 Factor: Patient ability to use |
Q9_2 |
This patient’s understanding of and comfort with the risks of this medication |
Q9_2 Factor: Understanding and comfort with risks |
Q9_3 |
This patient’s previous experience with treatments (over-the-counter and prescription) |
Q9_3 Factor: Patient’s previous experience |
Q9_4 |
This patient’s medical and health context (e.g., medical history, comorbidities, family history) |
Q9_4 Factor: Medical and health context |
Q9_5 |
Considerations of this patient’s access to the product (e.g., cost, insurance) |
Q9_5 Factor: Patient access |
Q9_6 |
Extent, duration, and severity of this patient’s symptoms |
Q9_6 Factor: Symptoms |
Q9_7 |
Patient’s preference for a mode of administration |
Q9_7 Factor: Patient preference for administration |
Q9_8 |
Potential duration of treatment use/course |
Q9_8 Factor: Duration |
Q9_9 |
Other (please specify) |
Q9_9 Factor: Other |
Value |
Value Label |
1 |
Selected |
0 |
Not selected |
Question Type: Multi-Punch
Question Q10
Variable Name: Q10
Variable Label: Q10 Top three questions from patients about using vaginal inserts
Question Text: What are the top three comments or questions you have you heard from patients about using vaginal inserts to treat vulvar and vaginal atrophy? (Select up to three.)
//PROGRAMMING NOTE: ALLOW PARTICIPANTS TO SELECT UP TO THREE ANSWERS//
[//Multi-punch//]
Variable Name |
Variable Text |
Variable Label |
Q10_1 |
Pros about vaginal inserts’ application method |
Q10_1 Pros application method |
Q10_2 |
Hearing positive things about how well vaginal inserts work |
Q10_2 Heard positive things |
Q10_3 |
Whether vaginal inserts may be safer than other estrogen treatments |
Q10_3 Inserts safer than other estrogen |
Q10_4 |
A desire to try something new |
Q10_4 Try something new |
Q10_5 |
Cons about vaginal inserts’ application method |
Q10_5 Cons application method |
Q10_6 |
Concerns about insurance coverage or cost |
Q10_6 Insurance coverage/cost |
Q10_7 |
Hearing negative things about how well vaginal inserts work |
Q10_7 Hearing negative things |
Q10_8 |
Concerns about using an estrogen treatment |
Q10_8 General concerns re: estrogen |
Q10_9 |
Other (specify) |
Q10_9 Other |
Value |
Value Label |
1 |
Selected |
0 |
Not selected |
Question Type: Multi-Punch
Question Q11
Variable Name: Q11
Variable Label: Q11 Top three topics talk to patients about vaginal inserts
Question Text: What are the top three topics that you prioritize when talking to your patients about vaginal inserts as a treatment option?
//PROGRAMMING NOTE: ALLOW PARTICIPANT TO SELECT UP TO THREE ANSWERS//
[RANDOM ORDER EXCEPT FOR LAST OPTION] [//Multi-punch//]
Variable Name |
Variable Text |
Variable Label |
Q11_1 |
How the product works |
Q11_1 Talking top 3: How product works |
Q11_2 |
Expected benefits of the product |
Q11_2 Talking top 3: Expected benefits |
Q11_3 |
Common side effects of the product |
Q11_3 Talking top 3: Common side effects |
Q11_4 |
Rare but serious side effects of the product |
Q11_4 Talking top 3: Rare serious effects |
Q11_5 |
Patient’s medical history (e.g., personal history or family history, possible co-morbidities) |
Q11_5 Talking top 3: Medical history |
Q11_6 |
The importance of using the product as directed |
Q11_6 Talking top 3: Importance of use as directed |
Q11_7 |
Other (Specify) |
Q11_7 Talking top 3: Other |
Value |
Value Label |
1 |
Selected |
0 |
Not selected |
//PROGRAMMING NOTE: If Q11D selected, display Q11_RISKS. OTHERWISE, PROCEED TO Q12 //
Question Type: Open End Essay
Question 11_RISKS
Variable Name: Q11_RISKS
Variable Label: Q11_RISKS Side effects discussed
Question Text: You said that you discuss rare but serious side effects of the product. What potential side effects do you discuss?
Question Type: Multi-Punch
Question Q12
Variable Name: Q12
Variable Label: Q12 How monitor for safety risks and side effects after prescribing vaginal inserts
Question Text: How do you most commonly monitor your patients for potential safety risks and side effects after prescribing vaginal inserts for vulvar and vaginal atrophy? Select all that apply.
Variable Name |
Value |
Variable Label |
Q12_1 |
I schedule routine follow-up appointments with patients. |
Q12_1 Monitor: Follow-up appointment |
Q12_2 |
I instruct patients to get bloodwork before follow-up appointment. |
Q12_2: Monitor: Bloodwork |
Q12_3 |
I instruct patients to call and schedule an appointment if they experience side effects. |
Q12_3 Monitor: Appointment if side effects |
Q12_4 |
I leave it to the patient to follow up if they feel a need to. |
Q12_4 Monitor: Leave up to patient |
Q12_5 |
A follow-up appointment is not necessary. |
Q12_5 Monitor: Follow-up not necessary |
Q12_6 |
Other (specify) |
Q12_6 Monitor: Other |
Value |
Value Label |
1 |
Selected |
0 |
Not selected |
Question Type: Grid
Question Q13
Variable Name: Q13
Variable Label: Q13 How often look for information on vaginal inserts
Question Text: How often do you look for information about vaginal inserts or other products from the following sources:
Variable Name |
Variable Text |
Variable Label |
Q13_ 1 |
Medical journals |
Q13_1 Info: Medical journals |
Q13_2 |
Medical websites or software (e.g. UpToDate, Epocrates, Medscape) |
Q13_2 Info: Medical websites or software |
Q13_3 |
Drug company/pharmaceutical representatives or their website |
Q13_3 Info: Drug company rep or website |
Q13_4 |
Go online/use a search engine (e.g., Google) |
Q13_4 Info: Online search |
Q13_5 |
Professional medical societies (e.g., publications, guidelines) |
Q13_5 Info: Professional medical societies |
Q13_6 |
Conferences |
Q13_6 Info: Conferences |
Q13_7 |
Discussion with colleagues (e.g., in person, email) |
Q13_7 Info: Discussion w/ colleagues |
Q13_8 |
FDA website or other FDA sources of information (e.g., email, alerts) |
Q13_8 Info: FDA |
Q13_9 |
Other government agencies (e.g., NIH, CDC) |
Value |
Value Label |
1 |
Never |
2 |
Rarely |
3 |
Sometimes |
4 |
Often |
//[SHOW QUESTION AT THE TOP OF THE SCREEN FOR QUESTION 14]//
The next question refers to boxed warnings, commonly referred to as black box warnings, on the product labeling for Vagifem, a vaginal tablet, and other estrogen products.
Question Type: Multi-Punch
Question Q14
Variable Name: Q14
Variable Label: Q14 Primary role of boxed warning
Question Text: In your opinion, what is the primary role of a boxed warning? Choose up to three options.
//Random Order, except last three
//PROGRAMMING NOTE: ALLOW PARTICIPANT TO UP TO SELECT THREE ANSWERS//
Variable Name |
Variable Text |
Variable Label |
Q14_1 |
To highlight if the product has risk of serious or life-threatening adverse effects |
Q14_1 BW Primary Role: Highlight most serious risks |
Q14_2 |
To provide information that should be factored into a decision to prescribe the product |
Q14_2 BW Primary Role: Provide prescribing information |
Q14_3 |
To provide an overview of the safety profile of the product |
Q14_3 BW Primary Role: Provide safety profile overview |
Q14_4 |
To disclose clinical trial and other product safety testing information |
Q14_4 BW Primary Role: Clinical trial and safety testing |
Q14_5 |
To provide information that prescribers should be communicating to patients |
Q14_5 BW Primary Role: Info to communicate to patients |
Q14_6 |
To provide information on how to safely use the product |
Q14_6 BW Primary Role: Info on how to safely use product |
Q14_7 |
I do not see a role for them |
Q14_7 BW Primary Role: No role for BW |
Q14_8 |
Other (specify) |
Q14_8 BW Primary Role: Other |
Q14_9 |
Unsure/Don’t know |
Value |
Value Label |
1 |
Included |
0 |
Not included |
//PROGRAMMING NOTE: SHOW PARAGRAPH ON ITS OWN PAGE//
The next set of questions will ask you more specifically about the boxed warning and prescribing information for Vagifem to treat vulvar and vaginal atrophy. This boxed warning appears on all prescription estrogen products.
//PROGRAMMING NOTE: “NEXT” BUTTON TO PROCEED TO Q15//
Question Type: Single Punch
Question Q15
Variable Name: Q15
Variable Label: Q15 Familiarity with BW for Vagifem and other estrogen products
Question Text: How would you rate your familiarity with the boxed warning information for Vagifem and other estrogen products?
Value |
Value Label |
1 |
Not at all familiar |
2 |
Slightly familiar |
3 |
Somewhat familiar |
4 |
Familiar |
5 |
Very familiar |
-99 |
Refused |
Question Type: Single Select Grid
Question Q16
Variable Name: Q16
Variable Label: Q16 Risks recalled from vaginal insert boxed warning
Question Text: Which of the following risks do you recall being included in the boxed warning for vaginal inserts? Please indicate a response for each risk.
[RANDOM ORDER EXCEPT FOR LAST OPTION]
Variable Name |
Variable Text |
Variable Label |
Q16_1 |
Endometrial cancer |
Q16_1 Risks: Endometrial cancer |
Q16_2 |
Endometrial hyperplasia |
Q16_2 Risks: Endometrial hyperplasia |
Q16_3 |
Dementia |
Q16_3 Risks: Dementia |
Q16_4 |
Stroke |
Q16_4 Risks: Stroke |
Q16_5 |
Deep vein thrombosis (DVT) |
Q16_5 Risks: Deep vein thrombosis |
Q16_6 |
Breast cancer |
Q16_6 Risks: Breast cancer |
Q16_7 |
Gallbladder disease |
Q16_7 Risks: Gallbladder disease |
Q16_8 |
Hypercalcemia |
Q16_8 Risks: Hypercalcemia |
Q16_9 |
Visual abnormalities |
Q16_9 Risks: Visual abnormalities |
Q16_10 |
Elevated blood pressure |
Q16_10 Risks: Elevated blood pressure |
Q16_11 |
Other (specify) |
Q16_12 Risks: Other |
Value |
Value Label |
1 |
Included |
2 |
Not included |
98 |
Don’t know |
//PROGRAMMING NOTE: SHOW PARAGRAPH ON ITS OWN PAGE, THEN CLICK NEXT TO VIEW BOXED WARNING//
We would like to show you some of the boxed warning information for Vagifem, which is available in the FDA-approved prescribing information. This boxed warning information appears on the labeling for all estrogen products. Please take a few moments to review this information.
//PROGRAMMING NOTE: SHOW THE BOXED WARNING ON ITS OWN PAGE, CAPTURE TIME SPENT ON BOXED WARNING//
[View boxed warning information]1
//PROGRAMMING NOTE: HAVE A “NEXT” BUTTON AT THE BOTTOM OF THE BOXED WARNING PAGE TO PROCEED TO QUESTION 17//
Question Type: Single Punch
Question Q17
Variable Name: Q17
Variable Label: Q17 Usefulness of BW for Vagifem
Question Text: How useful is the information in the boxed warning for Vagifem?
Value |
Value Label |
1 |
Not at all useful |
2 |
Slightly useful |
3 |
Somewhat useful |
4 |
Useful |
5 |
Very useful |
-99 |
Refused |
Question Type: Single Punch
Question Q18
Variable Name: Q18
Variable Label: Q18 Assessment of risk framing in Vagifem BW
Question Text: What is your assessment of the way the risks of Vagifem are framed in the boxed warning?
Value |
Value Label |
1 |
Strongly understates risk |
2 |
Somewhat understates risk |
3 |
Provides appropriate assessment of risk |
4 |
Somewhat overstates risk |
5 |
Strongly overstates risk |
6 |
Other (specify) |
-99 |
Refused |
Question Type: Single Punch
Question Q19
Variable Name: Q19
Variable Label: Q19 Assessment of benefits versus risks Post-BW
Question Text: Which statement best reflects your opinion on the relative benefits versus risks of vaginal inserts for patients with vulvar and vaginal atrophy.
Value |
Value Label |
1 |
The benefits of vaginal inserts outweigh the risks for most patients |
2 |
The benefits of vaginal inserts outweigh the risks for some, but not most, patients |
3 |
The benefits of vaginal inserts outweigh the risks for very few patients |
4 |
I am not familiar enough with vaginal inserts to make an assessment |
-99 |
Refused |
Question Type: Multi-Punch
Question Q20
Variable Name: Q20
Variable Label: Q20 How improve Vagifem boxed warning
Question Text: What would improve the boxed warning for Vagifem, in your opinion? (Select all that apply.)
Variable Name |
Variable Text |
Variable Label |
Q20_1 |
Nothing, the warning is fine the way it is |
Q20_1 Improve BW: Nothing |
Q20_2 |
Better evidence to support risk information |
Q20_2 Improve BW: Better risk info evidence |
Q20_3 |
Decrease the amount of information given/fewer words |
Q20_3 Improve BW: Decrease amount of info/shorten |
Q20_4 |
Simpler language |
Q20_4 Improve BW: Simpler language |
Q20_5 |
Formatting improvements (e.g., use of boldface) |
Q20_5 Improve BW: Formatting |
Q20_6 |
Increase the amount of information (e.g., statistics, more details) |
Q20_6 Improve BW: Increase amount of info |
Q20_7 |
Other (Specify) |
Q20_7 Improve BW: Other (specify) |
Q20_8 |
Make exclusive |
//Q20_8: Make exclusive//
Value |
Value Label |
1 |
Included |
0 |
Not included |
Question Type: Open-End Essay
Question Q21
Variable Name: Q21
Variable Label: Q21 Specific feedback on Vagifem BW information
Question Text: Please provide any specific feedback on the boxed warning information for Vagifem.
//PROGRAMMING NOTE: SHOW SENTENCE ON ITS OWN PAGE, THEN CLICK NEXT TO VIEW Q22//
Please now consider boxed warnings in general, not only the one you saw for Vagifem.
Question Type: Grid
Question Q22
Variable Name: Q22
Variable Label: Q22 Degree agree or disagree with BW statements
Question Text: To what degree do you agree or disagree with the following statements about boxed warnings in general (in other words, across all classes of prescription drugs)?
Value |
Value Label |
1 |
Strongly disagree |
2 |
Disagree |
3 |
Neither agree nor disagree |
4 |
Agree |
5 |
Strongly agree |
98 |
Unsure/Don’t know |
Question Type: Single Punch
Question Q23
Variable Name: Q23
Variable Label: Q23 General favorability of BW
Question Text: How favorable is your opinion of boxed warnings in general (across all classes of prescription drugs)?
Value |
Value Label |
1 |
Very unfavorable |
2 |
Somewhat unfavorable |
3 |
Neither unfavorable nor favorable |
4 |
Somewhat favorable |
5 |
Very favorable |
98 |
Unsure/Don’t know |
-99 |
Refused |
Question Type: Open End Essay
Question Q24
Variable Name: Q24
Variable Label: Q24 Suggestions for better using BW to highlight safety info
Question Text: In general, what suggestions do you have on how to better use boxed warnings as a tool to highlight important safety information?
//PRETEST ONLY//
//DISPLAY TEXT//
We would like your feedback on the survey that you completed. This will help FDA improve the survey for future use with healthcare providers.
Question Type: Single Punch
Question P1
Variable Name: P1
Variable Label: P1 One session completion
Question Text: Were you able to complete the survey in one session?
Value |
Value Label |
1 |
Yes |
0 |
No |
Question Type: Single Punch
Question P2
Variable Name: P2
Variable Label: P2 Participant Experience with Survey
Question Text: How would you rate your experience taking the survey?
Value |
Value Label |
1 |
Poor |
2 |
Fair |
3 |
Good |
4 |
Very good |
5 |
Excellent |
-99 |
Refused |
Question Type: Open End Essay
Question P3
Variable Name: P3
Variable Label: P3 Difficulty answering question
Question Text: Were there any questions you had difficulty answering? If yes, please explain.
Question Type: Open End Essay
Question P4
Variable Name: P4
Variable Label: P4 Other feedback
Question Text: What other suggestions of feedback about this survey would you like to share?
//DISPLAY FOR BOTH PRETEST AND MAIN STUDY//
Thank you for taking this survey. Your time is greatly appreciated.
1 NIH NLM (2019). LABEL: VAGIFEM- estradiol insert. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5ad3cf6-dd96-4e64-af21-c1eee38d0b88
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
Author | Lauren Burr |
File Modified | 0000-00-00 |
File Created | 2021-01-13 |